Blood-thinning medicine to prevent clots during pancreatic cancer treatment
Tests extra clot prevention in people with pancreatic cancer receiving pre-surgery treatment.
Key facts
- Who runs it
- HUS-Yhtymae
- Where
- Helsinki, Oulu, Tampere, and Turku, FinlandSee the 4 sites
- Registry title
- Prevention of thromboembolism during pancreatic cancer treatments - link to prognosis and relapse of the disease.
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 214 people, planned
- Started
- 27 Nov 2024
- Expected to end
- 1 Jan 2035
- Type of study
- Interventional
- Record updated
- 27 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic cancer who are about to start treatment before surgery (neoadjuvant treatment). It studies blood-clot prevention during that treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Pancreatic cancer, with treatment before surgery (neoadjuvant treatment) being planned.
- Earlier treatment
- Must not already be taking blood-thinning (anticoagulant) medicine.
Main reasons for not taking part
- Cannot use tinzaparin (a blood thinner) for medical reasons
- Already taking blood-thinning (anticoagulant) medicine
- Another active cancer in the past five years
- Severe kidney failure
- Tendency to bleed
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- An adult pancreatic cancer patient for whom neoadjuvant treatments are being planned due to pancreatic cancer
Who cannot take part
- The study excludes patients, if they have contraindications for using tinzaparin, are already on anticoagulant medication, have had any other active cancer in the past five years or have severe kidney failure or bleeding tendencies
Where in Finland
- HUS-YhtymaeHelsinki, FinlandTaking people
- Oulu University HospitalOulu, FinlandTaking people
- Tampere University HospitalTampere, FinlandTaking people
- Turku University HospitalTurku, FinlandTaking people
About the trial
What the trial wants to find out
Neoadjuvant-treated pancreatic cancer patients are at increased risk of thrombosis. Our aim is to investigate the impact of thromboprophylaxis administered during neoadjuvant treatments on the risk of vascular events and survival prognosis in pancreatic cancer patients in a randomized prospective study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Thrombosis prophylaxis and coagulation activation during neoadjuvant treatment in pancreatic cancer - Association to prognosis and recurrence.
- Plain-language title
- Blood-thinning medicine to prevent clots during pancreatic cancer treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 November 2024